Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchKyowa Kirin International announces expanded access to POTELIGEO® for adults with mycosis fungoides and Sézary syndrome in Central and Eastern Europe.
Kyowa Kirin International and Swixx BioPharma have announced that POTELIGEO® (mogamulizumab) has been approved for reimbursement by health authorities in Croatia and Bulgaria for adults suffering from mycosis fungoides and Sézary syndrome, marking a significant milestone for these under-served patients.
Company Information
Company
Kyowa Kirin International
Location
Galashiels, Scotland, United Kingdom
About
Kyowa Kirin International (KKI) is driven by a deep commitment to life, dedicated to addressing the unmet medical needs of patients, their families, and the healthcare professionals who support them. With a team of over 700 people, KKI is a rapidly growing specialty biopharmaceutical company focused on developing and commercializing innovative medicines in oncology, nephrology, and central nervous system (CNS) therapies across Europe and the Middle East.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Kyowa Kirin International ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.